Evidence checklist
Fatty Liver Disease
Evidence strength
Mark what you already have below and your evidence strength appears here.
Specialist opinion
Highest value0 of 4 collectedImaging documenting increased echogenicity on ultrasound, or decreased attenuation on CT, or signal loss on MRI consistent with hepatic steatosis. MRI-PDFF provides quantitative fat fraction.
Not marked
FibroScan results providing controlled attenuation parameter (CAP) for steatosis grading and liver stiffness measurement for fibrosis staging — critical for determining NAFLD vs. NASH with fibrosis.
Not marked
A medical opinion connecting NAFLD/NASH to service-connected diabetes, obesity, hypertriglyceridemia, or metabolic syndrome conditions that arose or worsened during service.
Not marked
Pathology report from liver biopsy documenting NAS (NAFLD activity score), hepatocyte ballooning, lobular inflammation, and fibrosis stage (F0–F4) — the gold standard for NASH diagnosis.
Not marked
Treatment records
0 of 2 collectedSerial liver panels showing ALT/AST elevation patterns, and metabolic labs documenting associated conditions (dyslipidemia, insulin resistance) that support the NAFLD diagnosis.
Not marked
Hepatology or gastroenterology records documenting weight management efforts, dietary counseling, management of metabolic risk factors, and any clinical trial participation.
Not marked
Lay statements
0 of 1 collectedA written statement from someone who can describe observable symptoms and how your condition affects daily life.
Not marked
Benefits questionnaire
0 of 1 collectedStandardized form capturing steatosis and fibrosis staging, liver function results, complications, and functional impact.
Not marked
Service records
0 of 1 collectedMilitary medical records showing in-service treatment, complaints, or injuries related to this condition.
Not marked
What you mark here is saved in this browser, on this device only — not to an account. Changing the target rating shows different items, but never loses what you have already marked.
